Slide 1: Presentation for investors, analysts and media
Presentation for investors, analysts and media Basel, 14 August, 2024 1 This presentation contains forward-looking statements that reflect the current views of management, and which are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or
Slide 2: Agenda: Highlights, Financials, Strategy, Outlook, Q&A
Highlights Guillaume Daniellot Financials Yang Xu Recent achievements & strategy Guillaume Daniellot Outlook 2024 Guillaume Daniellot Q&A Guillaume Daniellot, Yang Xu 3 3 Guillaume Daniellot, CEO 4
Slide 3: H1 2024 highlights
Revenue in CHF Organic revenue growth1 Core profitability 1.3 bn 16.1% 27.8% CHF 655 m revenue in the second quarter 14.8 % organic growth1 in Q2, 28.9% at constant FX2, IFRS EBIT margin 26.4% currency headwinds (12.4% in CHF) strong currency headwinds Consumer presence Implantology Updated outlook
Slide 4: Q2 2024 revenue and regional organic growth
Yang Xu, CFO 7 7 Regional % +12.4% +14.8% share of organic growth Organic 8 655 39 9% LATAM 11% NAM 9 29 34% EMEA 583 7 570 -20 Change in organic growth 46% APAC +12.4% 1 +5.3% +33.8% +14.9% Revenue FX effect M&A effect Adjusted EMEA NAM APAC LATAM Revenue Q2 2024 Q2 2023 revenue base Q2 2024 8 1 in
Slide 5: Gross profit margin and EBIT margin bridges
75.3 0.0 -180 bps 74.3 -1.0 0.1 72.5 72.1 -1.9 -0.3 IFRS gross Non-core FX effect Core gross Portfolio Productivity Core gross Non-core IFRS gross profit margin items profit margin mix effect effect profit margin items profit margin HY1 2023 HY1 2023 HY1 2024 HY1 2024 @FX 2023 @FX 2024 @FX 2024 @FX
Slide 6: Free cash flow and H1 2024 income statement
Free Cashflow CHF 145m (11.4% of Net Revenue) in H1 2024 vs. CHF 143m (12.5% of Net Revenue) in H1 2023 -18.7% 203 -117 -156 410 -7 334 Cash Net Cash Net Cash Net Cash Less cash from Cash 1 Jan Operating Investing Financing & Other discontinued operations 30 Jun 2024 2024 11 11 In CHF million, round
Slide 7: Continuing operations growth and core EBIT margin
Organic revenue Core EBIT Core EBIT growth margin margin (2023 FX1)) Continuing +16.1% 27.8% 28.9% operations Group incl. +12.9% 24.9% 26.0% disc. ops. 13 1 at 2023 full-year average FX rates 13 Tooth replacement Tooth alignment Digital solutions and restoration 14 14
Slide 8: Innovations shown at ITI
Guillaume Daniellot, CEO 15 15 Innovations shown at ITI new iExcel Straumann Falcon Sirios 16 16
Slide 9: End-to-end digital user experience in AXS
CBCT IOS Clear Aligner Smile in a Box Straumann UN!Q 17 17 mann AX End-to-end digital user rau S St experience in AXS Enhanced portfolio Service excellence Planning Design Manufacturing 18 18
Slide 10: Unified prosthetic platform testimonial
“A unified prosthetic platform with a single abutment connection is a game changer. It makes implant dentistry safer and more efficient.” Dr. German Gallucci, Boston, MA 19 19 Technology Service Go-to-market 20 20
Slide 11: DrSmile sale and management changes
o Based in Spain, Barcelona o Leading provider for direct-to-consumer o Wide product range - Clear aligners, professional aligners in Europe whitening and veneers o Established marketing teams o Tech Stack - Advanced technology & AI-optimized o Partner network of dental professionals in app Europe o
Slide 12: Growth ambition 2030 confirmed
23 23 Market environment and assumption Revenue and profitability • Uncertain economic environment remains • Organic revenue growth in the low double-digit percentage range • Group believes global patient flow should remain stable • Profitability in the 27-28% range at constant 2023 currency rates1
Slide 13: Upcoming investor events
25 25 2024 Event Location 15-16 Aug Jefferies Roadshow London 4-5 Sep Goldman Sachs European Med-tech Conference London 10-11 Sep Kepler Cheuvreux Autumn Conference Paris 18-19 Sep Bank of America Global Healthcare Conference London 29 Oct Straumann Q3 results 26 26
Slide 14: Revenue and cost breakdown, exchange rates, FX sensitivity
Revenue breakdown H1 2024 Exchange rates development 2023 – Jun 2024 110 . Other EUR 20.0% 26.0% 100 CHF BRL 1.5% 6.2% 90 CNY 14.6% 80 12/2022 03/2023 06/2023 09/2023 12/2023 03/2024 06/2024 USD/CAD/AUD 31.7% USDCHF EURCHF CNYCHF BRLCHF Total cost breakdown H1 2024 FX sensitivity Average exchange ra
Slide 15: H1 2024 IFRS to core reconciliation
H1, 2024 (in CHF 1 000) IFRS M&A Restructuring Legal cases CORE Revenue 1 273 232 0 1 273 232 Cost of goods sold (354 833) 2 877 1 492 (350 464) Gross profit 918 399 2 877 1 492 0 922 768 Other income 6 379 6 379 Distribution expense (241 273) 3 199 76 (237 997) Administrative expense (347 446) 5 12